Novartis's COSENTYX (Secukinumab) Approved by the FDA for Pediatric Hidradenitis Suppurativa: Only IL-17A Inhibitor Cleared for Adolescents Aged 12+

AI Briefing

• – Novartis's COSENTYX (Secukinumab) approved for pediatric hidradenitis suppurativa, FDA clears only IL-17A inhibitor for adolescents aged 12+, FDA approval marks a significant milestone in the treatment of this rare skin condition.